Resona Asset Management Co.,Ltd. Alnylam Pharmaceuticals, Inc. Transaction History
Resona Asset Management Co.,Ltd.
- $20.6 Billion
- Q3 2025
A detailed history of Resona Asset Management Co.,Ltd. transactions in Alnylam Pharmaceuticals, Inc. stock. As of the latest transaction made, Resona Asset Management Co.,Ltd. holds 41,497 shares of ALNY stock, worth $18.7 Million. This represents 0.09% of its overall portfolio holdings.
Number of Shares
41,497
Previous 43,700
5.04%
Holding current value
$18.7 Million
Previous $14.3 Million
32.79%
% of portfolio
0.09%
Previous 0.07%
Shares
7 transactions
Others Institutions Holding ALNY
# of Institutions
806Shares Held
116MCall Options Held
584KPut Options Held
648K-
Capital World Investors Los Angeles, CA16.8MShares$7.55 Billion0.83% of portfolio
-
Vanguard Group Inc Valley Forge, PA13.3MShares$5.98 Billion0.07% of portfolio
-
Black Rock Inc. New York, NY9.55MShares$4.29 Billion0.05% of portfolio
-
Capital Research Global Investors Los Angeles, CA7.19MShares$3.23 Billion0.49% of portfolio
-
T. Rowe Price Investment Management, Inc. Baltimore, MD4.28MShares$1.92 Billion0.88% of portfolio
About ALNYLAM PHARMACEUTICALS, INC.
- Ticker ALNY
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 123,028,000
- Market Cap $55.3B
- Description
- Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system...